雷珠单抗生物类似药SB11(Byooviz)与参照药Lucentis的免疫原性及其与疗效、安全性和药代动力学的关联:一项3期随机临床试验的事后分析
该事后分析基于一项3期随机双盲等效性试验,纳入705例新生血管性年龄相关性黄斑变性(nAMD)患者,比较SB11与参照雷珠单抗的免疫原性及其与疗效、安全性和药代动力学的关联。第52周抗药抗体(ADA)总阳性率为4.9%(32/657)。ADA阳性与阴性组间最佳矫正视力(BCVA)和中心亚视野厚度(CST)差异无统计学意义。作者认为免疫原性未与SB11和参照雷珠单抗的疗效和安全性相关,支持二者生物相似性。
要点
- 第52周ADA总阳性率为4.9%(32/657)。
- ADA阳性与阴性组间BCVA和CST差异无统计学意义。
- ADA阳性组眼内炎症相关事件为1/32(3.1%),ADA阴性组为4/620(0.6%)。
核心结论
- 作者认为,这项等效性试验的事后分析结果提示,免疫原性未与SB11和参照雷珠单抗在nAMD受试者中的疗效和安全性相关。
- ADA总发生率低,未发现ADA总阳性与药代动力学之间的明确关联。
- 作者认为这些发现支持SB11与参照雷珠单抗的生物相似性,未发现SB11相对于参照雷珠单抗与免疫原性相关的安全性问题。
研究设计与样本
- 这是一项随机、双盲、平行组3期等效性研究的事后分析,参与者来自9个国家75个中心,研究于2018年3月14日至2019年12月9日进行。
- 纳入标准为年龄50岁及以上、患有nAMD且存在活动性中心凹下脉络膜新生血管病变的受试者。
- 干预为玻璃体腔内注射SB11或参照雷珠单抗0.5 mg,每4周一次至第48周。
- 共纳入705例参与者,平均(标准差)年龄74.1(8.5)岁,女性403例(57.2%)。
主要发现
- 第52周ADA总阳性率为4.9%(32/657)。
- 截至第52周,ADA总阳性组与ADA阴性组之间BCVA的最小二乘均值(标准误)差异为1.6(2.2)字母(95%CI,-2.7至5.8;P=0.46),CST差异为3(13)μm(95%CI,-23至29;P=0.83)。
- 眼内炎症相关事件在ADA总阳性组中发生1/32例(3.1%),在ADA总阴性组中发生4/620例(0.6%)。
- ADA总阳性组的血清雷珠单抗浓度随时间略低于ADA阴性组,最高值分别为第16周的1389.3(875.4)pg/mL与第36周的1665.4(1124.0)pg/mL。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: SB11 and reference ranibizumab (RBZ) are monoclonal anti-vascular endothelial growth factor (VEGF)-A antibodies approved for the treatment of neovascular age-related macular degeneration (nAMD) and other retinal diseases. The association of ranibizumab immunogenicity and treatment outcomes in patients with nAMD is unclear but relevant regarding concerns about immunogenicity of anti-VEGF biological products. OBJECTIVE: To examine the association of immunogenicity to ranibizumab products (SB11 and RBZ) with efficacy, safety, and pharmacokinetics. DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc analysis of a randomized, double-masked, parallel-group phase 3 equivalence study with participants from 75 centers in 9 countries conducted from March 14, 2018, to December 9, 2019. Included were participants 50 years or older with nAMD and active subfoveal choroidal neovascularization lesions. INTERVENTIONS: Intravitreal injection of SB11 or RBZ, 0.5 mg, every 4 weeks through week 48. MAIN OUTCOMES AND MEASURES: Serum antidrug antibodies (ADAs) were analyzed during the study period until week 52 to measure immunogenicity. Analyses were performed on immunogenicity (overall ADA positivity) with best-corrected visual acuity (BCVA) and central subfield thickness (CST). Adverse events associated with intraocular inflammation (IOI) and serum ranibizumab levels were compared between overall ADA-positive and ADA-negative participants. RESULTS: A total of 705 participants (mean [SD] age, 74.1 [8.5] years; 403 female individuals [57.2%]) were included in the study. The overall incidence of ADA-positivity was 32 of 657 (4.9%) at week 52. The least-squares mean (SE) differences between overall ADA-positive and ADA-negative participants up to week 52 for BCVA and CST, respectively, were 1.6 (2.2) letters (95% CI, -2.7 to 5.8; P = .46) and 3 (13) μm (95% CI, -23 to 29; P = .83). IOI-related events occurred in 1 of 32 overall ADA-positive participants (3.1%) and 4 of 620 overall ADA-negative participants (0.6%). Mean (SD) serum ranibizumab concentrations over time were slightly lower in overall ADA-positive participants compared with those of ADA-negative participants, with a maximum value of 1389.3 (875.4) pg/mL at week 16 vs 1665.4 (1124.0) pg/mL at week 36, respectively. CONCLUSIONS AND RELEVANCE: Results of this post hoc analysis of an equivalence trial suggest that immunogenicity was not associated with efficacy and safety of SB11 and RBZ in participants with nAMD. With a low overall ADA incidence, no clear association was identified between overall ADA positivity and pharmacokinetics. These findings support the biosimilarity of SB11 and RBZ, with no safety concern identified for SB11 vs RBZ associated with immunogenicity. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03150589.
引用
- Bressler NM, Kim T, Oh I, et al. Immunogenicity With Ranibizumab Biosimilar SB11 (Byooviz) and Reference Product Lucentis and Association With Efficacy, Safety, and Pharmacokinetics: A Post Hoc Analysis of a Phase 3 Randomized Clinical Trial. JAMA Ophthalmol. 2023. PMID: 36520462. doi:10.1001/jamaophthalmol.2022.5403
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。